Electrochemistry
FeMn single-atom nanozyme dual-readout HER2 test
Open access · cc by · source: Europe PMC
An etched FeMn–N–C nanozyme boosts peroxidase-like activity 2.03-fold and reports HER2 by electrochemistry and 808 nm photothermal readout.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
This library holds 17 empirical chemistry papers on electrochemistry with isolated findings, rates or spectra rather than reviews.
Evidence for the claim as stated.
An etched FeMn–N–C nanozyme boosts peroxidase-like activity 2.03-fold and reports HER2 by electrochemistry and 808 nm photothermal readout.
Evidence for the claim as stated.
Study at a glance
- Design
- Animal / in-vitro — FeMn–N–C nanozyme sandwich immunoassay with electrochemical and 808 nm photothermal readouts versus ELISA
- N
- N=5 · Five hospital sera compared with commercial HER2 ELISA; calibration n = 6–7
- Population
- Human serum HER2 immunoassay samples plus TMB/H2O2 nanozyme assays
- Outcome
- Etched FeMn–N–C raises peroxidase-like activity 2.03-fold and dual readouts agree with commercial HER2 ELISA
Structured fields used in claim comparison tables when every cited study has a complete layer.
Inspect source passages
FeMn single-atom nanozyme dual-readout HER2 test
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
How is POD activity assayed?
the absorbance at 652 nm was quantified
How was serum accuracy checked?
All experimental values ( t exp ) were found to be below the critical value ( t crit ) of 2.78
Key findings
FeMn-NCetch/SAC is 2.03× more POD-active than Fe-NC/SAC. Dual electrochemical and 808 nm photothermal signals agree with a commercial HER2 ELISA (texp < 2.78).
Methodology
Authors pyrolyzed ZnO@ZIF-8 to N-doped carbon, doped Fe/Mn, etched defects, assayed TMB/H2O2 POD activity, built a sandwich immunoassay, and compared five hospital sera to ELISA.
Limitations
This is a five-sample serum comparison, not a multicenter diagnostic trial; ‘biotherapeutic’ potential is speculative.
Related papers in this topic
Same topic cluster — not a recommendation engine.